Background

ETX101 is an investigational therapy for children with Dravet syndrome who carry SCN1A mutations. Current standard of care relies on antiepileptic drugs to suppress seizures. Existing agents have limited efficacy and a high risk of adverse events, creating substantial demand for novel treatments. This clinical trial is designed to address this unmet need.

Clinical Design

ENDEAVOR is a multi‑center, Phase 1/2 study conducted in two parts, enrolling infants and toddlers aged 6 months to 36 months as well as children and adolescents aged 48 months to 18 years. Part 1A employs an open‑label dose‑escalation design, Part 1B uses an open‑label single‑dose design, and Part 2 is a randomized, double‑blind, placebo‑controlled (sham delayed‑treatment) segment.

Expected Impact

If ETX101 demonstrates superior seizure‑control efficacy and an improved safety profile relative to existing antiepileptics, it could substantially shift the treatment paradigm for Dravet syndrome. Early intervention in the infant cohort may also minimize long‑term neurodevelopmental injury.

Industry Implications

Dravet syndrome is a rare disease with a small market size, but it requires high‑priced, chronic therapy. Success would enable Encoded Therapeutics to expand its rare neuro‑disease portfolio and generate revenue growth through partnerships and licensing. Conversely, failure could lead to a reassessment of investment risk for other gene‑ or channel‑targeted therapeutics.